Navigation Links
Yongye Biotechnology International Retains CCG Investor Relations
Date:8/8/2008

BEIJING, Aug. 8 /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB) ("Yongye" or the "Company"), a leading developer, producer and distributor of nutrients for plants and animals in the People's Republic of China, today announced that it has retained CCG Investor Relations to assist in the design and execution of its investor relations program.

Yongye is engaged in the development, distribution and sales of fulvic acid based liquid and powder nutrients for plants and animals. Yongye currently markets and sells its nutrients for plants in ten provinces and its nutrients for animals in four provinces. The Company sold 106,000 units (approximately 1,100 metric tons) of nutrients for plants and 13,800 units (approximately 4 metric tons) of nutrients for animals in 2007. Nutrients for plants contributed 87%, and nutrients for animals contributed 13%, of the Company's $13.1 million total revenue in 2007. In the first quarter of 2008, the Company sold 75,500 units of nutrients for plants (approximately 756 metric tons) and 47,035 units of nutrients for animals (approximately 14 metric tons), which contributed 83% and 17%, respectively, of the Company's $9.5 million total revenue.

"Our proprietary technology for fulvic acid extraction produces some of the purest and most bioactive fulvic acid in China. We combine this fulvic acid base with other ingredients using our proprietary formulae to create some of the most effective nutrients for plants and animals available in China. We plan to increase distribution and sales within our existing markets in the third and fourth quarters of 2008, and help our customers consistently achieve reliable results through use of our high quality products," said Mr. Zishen Wu, Chairman and CEO of Yongye Biotechnology International, Inc. "Along with expanding our operations, we look forward to working with CCG to improve our visibility in the investment community and with the financial media."

"China has a total of 155 million hectares of arable farmland. China's large population means that its arable farmland must feed an average of 10 people per hectare compared to a worldwide average of 4.4 people per hectare. China's farmland is currently being used at close to capacity levels just to meet domestic demand. A combination of limited arable land and a large and growing population has created a significant need to increase output per hectare in China," commented Crocker Coulson, President of CCG Investor Relations. "We look forward to helping Yongye achieve a strong dialogue with US investors."

About Yongye Biotechnology International, Inc.

Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the development, distribution and sales of fulvic acid based nutrients for plants and animals. The Company's patent pending processes and proprietary formulas allow it to create products which increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia. The Company sells its products through distributors and directly to farmers located in ten provinces throughout China.

Forward-looking Statements

Certain statements set forth in this press release constitute "Forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. All such forward-looking statements involve risks and uncertainties, including, but not limited to: statements regarding the Company's products; marketing and sales; patents and regulatory approvals; the effect of competition and proprietary rights of third parties; the need for and availability of additional financing and access to capital; the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with other companies. There can be no assurance that such forward-looking statements will prove to be accurate and Yongye undertakes no obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.

For more information, please contact:

Yongye Biotechnology International, Inc.

Mr. Larry Gilmore-VP of Corporate Strategy

Tel: +1-818-390-1272

Email: larry.gilmore@gmail.com

CCG Investor Relations, Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE Yongye Biotechnology International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
2. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. New Book on the Business of Biotechnology
5. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
6. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
7. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
8. Pennsylvania Governor Rendell Says State Number 1 in New Biotechnology Study
9. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
10. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
11. Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and ... clinical trial team. , Using the CONSULT module, patients and physicians can schedule a ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology:
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
Breaking Biology News(10 mins):